Table 1.
Patient Characteristics according to Final Diagnosis.
Fig 1.
The distribution of FNA-Tg in lymph node metastasis and benign groups according to the TgAb.
(A) Comparison of FNA-Tg levels in all groups. (B) Comparison of FNA-Tg levels in the sTgAb- group. (C) Comparison of FNA-Tg levels in the sTgAb+ group. The cutoff values of FNA-Tg between malignant and benign lymph nodes were presented as arrows (19.9 [= exp (2.989)] ng/mL in a, 19.9 [= exp (2.989)] ng/mL in b, 38.3 [= exp (4.256)] ng/mL in c, respectively). The abscissa represents the logarithmically transformed values of FNA-Tgs to adjust for skewed distributions. sTgAb-, undetectable serum TgAbs; sTgAb+, detectable serum TgAbs; All groups, sTgAb- and sTgAb+ groups being included together; FNA-Tg, thyroglobulin level in FNA washout fluid; LN, lymph node.
Table 2.
Diagnostic performances of FNA-Tg according to the presence of serum TgAbs.
Table 3.
Diagnostic performance comparison between FNA alone and the combination of FNA with FNA-Tg.
Table 4.
Review of diagnostic performances of FNA-Tg and the combination of FNA with FNA-Tg.